Yes, I thought that was only in Spanish but sometimes also used in English so I removed the question. May I ask as this will be easier, "do you got?" what is your native language? I speak 5, I would prefer you understood my reply. This is getting silly.
Are you this guy Docteur? https://m.facebook.com/pages/category/Song/MEBStudioprod/posts/ Look, if I discuss a specific logical fallacy and you have no clue what it is, you will skip over this gap like many do with a bit from another language. We all do it sometimes with bla bla words.
Even if lupus patients taking hydroxy become infected and ill with corona, that will not necessarily be an indictment of the drug. Lupus patients have seriously impaired immune systems. If hydroxy gives non-lupus patients even just a little 20% edge that might be enough to keep them from going from sick to critical but might not be enough for a lupus patient. Doesnt mean that it still would not be beneficial for the masses or many anyway. We don't know yet.
My point is that there are looking at Medicare databases to find if people who were taking HCQ previously to the outbreak have become infected, and as I understand they have not found anyone yet. 'Yet' being the operative word. Hence my Q asking for evidence to nullify this hypo.
Great and you have comprehension problems in English so you are hopeless. Everyone use short words and sentences with this polydope.
Its not entirely your fault and a you cannot grasp native speakers as we use a lot of shortcuts. https://www.bbc.com/worklife/articl...h-speakers-are-the-worlds-worst-communicators
"Lupus patients are not getting sick from CCP virus" It is time that we started calling out dangerous and incorrect medical bullshiat directly. There Is No Study Proving That ‘Lupus Patients Don’t Get Coronavirus’ Because They Take Hydroxychloroquine Rumors are circulating about a study that shows people with lupus don’t get COVID-19, but emerging data says otherwise. You may have seen recent headlines suggesting that people with lupus, an autoimmune disease that affects about 1.5 million Americans, don’t contract coronavirus because many of them take hydroxychloroquine. This information is not true, and the Global Healthy Living Foundation needs to set the record straight based on data and medical expertise. Hydroxychloroquine — a first-line lupus therapy that is also commonly used to treat rheumatoid arthritis and other rheumatologic conditions — is currently being studied as a potential treatment for COVID-19 because of its anti-viral properties. But there is no conclusive evidence of its benefits for coronavirus yet. During a White House briefing Saturday April 4, President Trump suggested there was research showing that lupus patients did not get coronavirus. The implication was that perhaps taking hydroxychloroquine was protecting them. “They should look at the lupus thing. I don’t know what it says, but there’s a rumor out there that because it takes care of lupus very effectively as I understand it, and it’s a, you know, a drug that’s used for lupus,” President Trump said during the briefing. “So there’s a study out there that says people that have lupus haven’t been catching this virus. Maybe it’s true, maybe it’s not.” It is not true. Emerging Data on Lupus Patients and COVID-19 A couple of weeks ago, as the coronavirus pandemic was massively increasing in scale and impact, rheumatology researchers from around the globe started collaborating to collect data on patients with such conditions as lupus to answer questions exactly like this. Do patients with autoimmune conditions fare differently from COVID-19 than the general population? Do certain medications lead to better or worse outcomes? The registry is called the COVID-19 Global Rheumatology Alliance. (The Global Healthy Living Foundation and its arthritis patient community CreakyJoints was one of its first members and advisers.) More data is being collected daily and certainly it is too early to make any definitive conclusions about COVID-19 in rheumatology patients, but the data so far show that: Lupus patients do, in fact, get COVID-19. Many of them are taking hydroxychloroquine at the time of their diagnosis. According to information from the registry shared over the last few days on Twitter, the registry now has data on 110 patients. Most patients have rheumatoid arthritis (36 percent), followed by psoriatic arthritis and lupus (17 percent each). On April 2 — two days before the President’s recent statements about lupus and hydroxychloroquine — the registry Tweeted: “One frequently asked question: Over 25% of patients who developed a COVID-19 were on HCQ [hydroxychloroquine] at the time of diagnosis.” Last night, the registry tweeted: “Based on early data currently available in our registry, we are not able to report any evidence of a protective effect from hydroxychloroquine against COVID-19. A randomized, controlled trial would be the only way to study this to get a reliable answer to this question.” Rheumatologists who treat patients with lupus are concerned about rumors suggesting patients are less susceptible to COVID-19. Misinformation like this puts patients at risk, says rheumatologist Grace C. Wright, MD, PhD, founder and president of the Association of Women in Rheumatology (AWIR). “There is no data that hydroxychloroquine is protective against contracting COVID-19.” She, and many other rheumatologists the Global Healthy Living Foundation has spoken with over the last several days and weeks, worry that it could be a serious issue if people who take hydroxychloroquine mistakenly think they are protected from infection. Rheumatologist Robin K. Dore, MD, clinical professor of medicine at the David Geffen School of Medicine at UCLA, shared this message on her patient portal: To Dr. Dore’s patients who are taking Plaquenil (hydroxychloroquine), there is no evidence that this medication prevents one from developing a COVID-19 infection. This medication is now being studied to determine if it lessens the severity of the infection once a person has developed the disease. Dr. Dore urges you to continue social distancing, hand washing, and wearing a face covering when you are out in the public. Do not feel that you are immune to the virus if you are taking Plaquenil. Further updates will follow as appropriate. Concerns About Access to Hydroxychloroquine Other parts of the White House briefing continued to exacerbate fears among lupus and other rheumatology patients about having access to hydroxychloroquine, which has been in short supply due to its current use as an experimental COVID-19 therapy. President Trump urged Americans to take the medication: “What do you have to lose? Take it. I really think they should take it. But it’s their choice. And it’s their doctor’s choice or the doctors in the hospital. But hydroxychloroquine. Try it, if you’d like.” Messages like these could further impact the availability of this crucial medication for people who take it every day to prevent complications from lupus and other conditions. We have written before about how denying hydroxychloroquine prescriptions to rheumatology patients, which is occurring in the Kaiser Permanente health care system in California right now, for example, is dangerous and even life-threatening. We have also explained how hydroxychloroquine is used to treat lupus and other rheumatologic conditions. To reiterate some of those key points: “If a patient has to stop taking hydroxychloroquine, they are more likely to experience a flare,” says Ashira Blazer, MD, a rheumatologist at NYU Langone Health in New York City whose clinical research focuses on lupus. “And the last thing we want is for patients not to be able to take a drug that is helping them, then flare, then require heavier immunosuppressing drugs, then be more immunocompromised, and then contract COVID-19.” “Hydroxychloroquine is a safe, effective, and inexpensive therapy for conditions like lupus and rheumatoid arthritis,” says Dr. Blazer. “If there is a big shortage, it will exacerbate health disparities. People who need an effective and affordable drug won’t be able to get it. There is a risk of mortality, especially for minority women who are disproportionately affected by serious lupus complications, if hydroxychloroquine is not made available to our most vulnerable patients.”
@Dr. Love, your response? Welcome back GWB, great to see you quoting your source and about that other thing, I would never have revealed, only do that with actually evil people, not just wrong a lot. More serious matters for us all these days.